Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
TLR4 agonists have been proposed as immunotherapeutics in cancer. Here, the authors show the TLR4-dependent adjuvant effect of FimH, an E. coli adhesin, in promoting dendritic cell mediated-T cell activation and response to immune checkpoint blockade in preclinical cancer models.
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Portfolio
2020-03-01
|
| Cyfres: | Nature Communications |
| Mynediad Ar-lein: | https://doi.org/10.1038/s41467-020-15030-4 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|